Phreesia, Inc. (NYSE:PHR) Shares Bought by Nuveen Asset Management LLC

Nuveen Asset Management LLC grew its stake in Phreesia, Inc. (NYSE:PHR - Free Report) by 77.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 235,827 shares of the company's stock after acquiring an additional 102,662 shares during the period. Nuveen Asset Management LLC owned 0.41% of Phreesia worth $5,933,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in PHR. Deerfield Management Company L.P. Series C grew its stake in Phreesia by 133.6% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 1,271,832 shares of the company's stock worth $31,999,000 after acquiring an additional 727,384 shares in the last quarter. Greenhouse Funds LLLP grew its stake in Phreesia by 27.9% in the 4th quarter. Greenhouse Funds LLLP now owns 2,873,892 shares of the company's stock worth $72,307,000 after acquiring an additional 626,579 shares in the last quarter. Park West Asset Management LLC bought a new position in Phreesia in the 4th quarter worth about $10,657,000. Millennium Management LLC grew its stake in Phreesia by 83.2% in the 4th quarter. Millennium Management LLC now owns 653,634 shares of the company's stock worth $16,445,000 after acquiring an additional 296,863 shares in the last quarter. Finally, ExodusPoint Capital Management LP grew its stake in Phreesia by 448.6% in the 4th quarter. ExodusPoint Capital Management LP now owns 174,971 shares of the company's stock worth $4,402,000 after acquiring an additional 143,077 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on PHR. KeyCorp dropped their price objective on shares of Phreesia from $30.00 to $28.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 16th. Citigroup reiterated a "buy" rating on shares of Phreesia in a research note on Wednesday. Wall Street Zen raised shares of Phreesia from a "hold" rating to a "buy" rating in a research report on Sunday. Needham & Company LLC reissued a "buy" rating and set a $29.00 target price on shares of Phreesia in a research report on Thursday, March 13th. Finally, Canaccord Genuity Group decreased their target price on shares of Phreesia from $35.00 to $34.00 and set a "buy" rating for the company in a research report on Thursday. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $31.64.

Phreesia Stock Performance

Shares of NYSE PHR traded up $0.37 during midday trading on Monday, reaching $24.86. The company had a trading volume of 665,489 shares, compared to its average volume of 441,323. The business's 50-day simple moving average is $24.80 and its 200 day simple moving average is $25.31. The stock has a market cap of $1.48 billion, a P/E ratio of -16.91 and a beta of 0.74. Phreesia, Inc. has a 1 year low of $17.07 and a 1 year high of $30.53. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04.

Phreesia (NYSE:PHR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.06. The business had revenue of $115.94 million during the quarter, compared to analysts' expectations of $115.00 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The business's quarterly revenue was up 14.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.05) earnings per share. On average, analysts forecast that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Insider Transactions at Phreesia

In related news, COO Evan Roberts sold 7,233 shares of the firm's stock in a transaction on Tuesday, April 8th. The shares were sold at an average price of $23.85, for a total transaction of $172,507.05. Following the sale, the chief operating officer now owns 776,652 shares in the company, valued at approximately $18,523,150.20. This trade represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Balaji Gandhi sold 8,045 shares of the firm's stock in a transaction on Tuesday, April 8th. The shares were sold at an average price of $23.85, for a total transaction of $191,873.25. Following the sale, the chief financial officer now owns 108,411 shares in the company, valued at approximately $2,585,602.35. This represents a 6.91% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,474 shares of company stock worth $1,023,208 over the last 90 days. 5.50% of the stock is currently owned by company insiders.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.